このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Unity Biotechnology マネジメント

マネジメント基準チェック /34

Unity Biotechnology'sの CEO はAnirvan Ghoshで、 Mar2020年に任命され、の在任期間は 4.25年です。の年間総報酬は$ 1.26Mで、 48.3%給与と51.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.42%を直接所有しており、その価値は$ 98.01K 。経営陣と取締役会の平均在任期間はそれぞれ8.8年と5.9年です。

主要情報

Anirvan Ghosh

最高経営責任者

US$1.3m

報酬総額

CEO給与比率	48.3%
CEO在任期間	4.3yrs
CEOの所有権	0.4%
経営陣の平均在職期間	8.8yrs
取締役会の平均在任期間	5.9yrs

経営陣の近況

Recent updates

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Mar 05

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Dec 22

A Look Inside Unity Bio's Transition To An Ophthalmology Company

Nov 27

CEO報酬分析

Unity Biotechnology の収益と比較して、Anirvan Ghosh の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$1m	US$609k	-US$40m
Sep 30 2023	n/a	n/a	-US$31m
Jun 30 2023	n/a	n/a	-US$30m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$2m	US$580k	-US$44m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$59m
Mar 31 2022	n/a	n/a	-US$64m
Dec 31 2021	US$4m	US$562k	-US$61m
Sep 30 2021	n/a	n/a	-US$70m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$82m
Dec 31 2020	US$7m	US$417k	-US$94m

報酬と市場: Anirvanの総報酬 ($USD 1.26M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。

報酬と収益: Anirvanの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Anirvan Ghosh (60 yo)

4.3yrs

在職期間

US$1,260,838

報酬

Dr. Anirvan Ghosh, Ph D., serves as Chief Executive Officer and Director of Unity Biotechnology, Inc. since March 30, 2020. Dr. Ghosh had been Senior Vice President, Head of Research and Early Development...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Anirvan Ghosh	CEO & Director	4.3yrs	US$1.26m	0.42% $ 98.0k
Nathaniel David	Co-Founder & Executive Director	13.4yrs	US$55.20k	0.35% $ 81.3k
Lynne Sullivan	CFO & Head of Corporate Development	3.8yrs	US$771.59k	0.12% $ 28.3k
Alexander Nguyen	Chief Legal Officer	3.3yrs	US$677.80k	0.020% $ 4.7k
Jan van Deursen	Founder	13.4yrs	データなし	データなし
Judith Campisi	Founder	13.4yrs	データなし	データなし
Daohong Zhou	Founder	13.4yrs	データなし	データなし
Przemyslaw Sapieha	Chief Scientist	3.3yrs	データなし	データなし
Sharon Klier	Head of Ophthalmology & Chief Development Officer	no data	データなし	データなし

8.8yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: UBXの経営陣は経験豊富で経験豊富です（平均在職期間は8.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Anirvan Ghosh	CEO & Director	4.3yrs	US$1.26m	0.42% $ 98.0k
Nathaniel David	Co-Founder & Executive Director	12.6yrs	US$55.20k	0.35% $ 81.3k
Camille Samuels	Independent Director	9.3yrs	US$65.70k	0.0060% $ 1.4k
Paul Berns	Lead Independent Director	6.3yrs	US$92.70k	0.0019% $ 449.5
Keith Leonard	Chairman	8.4yrs	US$85.20k	0.13% $ 29.7k
Margo Roberts	Independent Director	5.5yrs	US$59.20k	0% $ 0
Michael Samar	Independent Director	2.1yrs	US$70.20k	0% $ 0
Gilmore O'Neill	Independent Director	3.5yrs	US$60.20k	0% $ 0

5.9yrs

平均在職期間

58.5yo

平均年齢

経験豊富なボード: UBXの取締役会は経験豊富であると考えられます ( 5.9年の平均在任期間)。

Unity Biotechnology マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024

Insufficient new directors

UNITY Biotechnology Announces Board Changes

Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022

Kristina Burow Resigns as Member of the Board and All of the Committees of the Board from Unity Biotechnology, Inc

Chief Medical Officer notifies of intention to sell stock

Recent updates

Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024

Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

Unity Biotechnology, Inc. announced delayed annual 10-K filing

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss

Insufficient new directors

Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

New major risk - Financial position

Price target decreased by 13% to US$6.80

UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

New major risk - Revenue and earnings growth

Price target increased by 12% to US$8.80

Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema (Dme)

Price target increased by 8.8% to US$7.83

Price target decreased to US$38.00

Unity Biotechnology, Inc. Announces Positive 24-Week Data from Phase 2 Behold Study of UBX1325 in Patients with Diabetic Macular Edema

Price target increased to US$75.17

Price target increased to US$90.00

UNITY Biotechnology falls 7% on reverse stock split

Price target increased to US$7.83

Unity Biotechnology, Inc. Completes Enrollment in Phase 2 Envision Study of UBX1325 in Wet Age-Related Macular Degeneration

Unity Biotechnology cuts stock sales agreement in half to $25M

Unity Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

Unity Biotechnology Announces Positive Data in Phase 2 Behold Study of Ubx1325 in Patients with Diabetic Macular Edema

Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

UNITY Biotechnology Announces Board Changes

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022

Price target increased to US$7.50

UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degenera

Unity Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

Kristina Burow Resigns as Member of the Board and All of the Committees of the Board from Unity Biotechnology, Inc

Price target increased to US$7.50

Unity Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

Unity Biotechnology, Inc. Announces the Design for Its Phase 2 Study of Ubx1325 in Wet Age-Related Macular Degeneration and Anticipated Milestones for 2022

Chief Medical Officer notifies of intention to sell stock

A Look At Unity's UBX1325 Phase 1 Results

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell 3000E Index

Price target increased to US$6.86

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020

Price target increased to US$6.20

Unity Biotechnology, Inc. Appoints Alexander Nguyen as General Counsel

Unity Biotechnology, Inc. Announces New Preclinical Research That Reveals A Novel Mechanism for Treating Age-Related Eye Diseases

New 90-day high: US$7.51

Unity Biotechnology, Inc. Appoints Przemyslaw (Mike) Sapieha as Chief Scientific Advisor

New 90-day high: US$6.47

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Unity Biotechnology Announces Executive Changes

A Look Inside Unity Bio's Transition To An Ophthalmology Company

New 90-day high: US$4.78

Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

New 90-day low - US$2.94

Price target lowered to US$5.67

Unity Biotechnology, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

New 90-day high - US$9.96

Price target raised to US$23.33

Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell Microcap Value Index

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

マネジメント基準チェック /34